www.summittxinc.com Open in urlscan Pro
178.62.55.168  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Summit Therapeutics PLC
Summit Therapeutics PLC
 * Open submenu (Our Company)Our Company
 * Open submenu (Our Programs)Our Programs
 * Clinical Trials
 * Open submenu (Innovation Engine)Innovation Engine
 * Scientific Literature & Publications
 * Open submenu (Investors & Media)Investors & Media
 * Careers

Close submenu (Our Company)Our Company
 * Strategy & Mission
 * Our Values
 * Leadership
 * Our Board
 * Our Scientific Advisors
 * Our Collaborations
 * Partnering Opportunities
 * Contact

Close submenu (Our Programs)Our Programs
 * Pipeline
 * C. difficile Infection
 * Enterobacteriaceae

Close submenu (Innovation Engine)Innovation Engine
 * Discuva Platform

Close submenu (Investors & Media)Investors & Media
 * Investor Center
 * Media Center
 * Press Releases
 * Announcements, Financial Reports & Filings
 * Email Alerts
 * Share Price Data
 * Corporate Governance
 * Board of Directors Diversity Matrix
 * Shareholder Meetings
 * Summit Presentations

 * Our Company
   * Strategy & Mission
   * Our Values
   * Leadership
   * Our Board
   * Our Scientific Advisors
   * Our Collaborations
   * Partnering Opportunities
   * Contact
 * Our Programs
   * Pipeline
   * C. difficile Infection
   * Enterobacteriaceae
 * Clinical Trials
 * Innovation Engine
   * Discuva Platform
 * Scientific Literature & Publications
 * Investors & Media
   * Investor Center
   * Media Center
   * Press Releases
   * Announcements, Financial Reports & Filings
   * Email Alerts
   * Share Price Data
   * Corporate Governance
   * Board of Directors Diversity Matrix
   * Shareholder Meetings
   * Summit Presentations
 * Careers


COMMITTED TO OPTIMIZING
HUMAN HEALTH




Partnering Opportunities 2022 Shareholders' Meetings


SUMMIT THERAPEUTICS

Summit is committed to leadership in resolving serious, unmet medical needs for
the betterment of overall HUMAN HEALTH.

Summit’s intention is to expand our pipeline product portfolio in the
therapeutic area of oncology and/or product offerings that are designed to work
in harmony with the human gut microbiome. We intend to enact this through
business development activities, including possible acquisitions and/or
collaborations in addition to internal research and discovery efforts.
We have assembled a world-class leadership team of accomplished executives to
guide Summit into the next chapter of growth.

You can view the full 2022 Shareholders Meeting here: Summit Therapeutics 2022
Shareholders Meeting

Download the Summit Therapeutics Corporate Brochure

Download


LATEST NEWS


NEWS / 17 NOV 2022


SUMMIT THERAPEUTICS APPOINTS EXPERIENCED CLINICAL LEADER DR. ALESSANDRA CESANO
TO ITS BOARD OF DIRECTORS


NEWS / 09 NOV 2022


SUMMIT THERAPEUTICS INC. REPORTS FINANCIAL RESULTS AND OPERATIONAL PROGRESS FOR
THE THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2022


NEWS / 20 OCT 2022


SUMMIT THERAPEUTICS PRESENTS RI-CODIFY TRIAL RESULTS FOR MICROBIOME-SPARING
RIDINILAZOLE AT IDWEEK 2022

View News Articles

> WE ARE BUILDING A VERY DIFFERENTIATED COMPANY THAT FOCUSES ON BRINGING
> INNOVATION TO THE TREATMENT OF HIGH UNMET MEDICAL NEEDS BY FOCUSING ON THE
> CAUSE OF THE CONDITION AND SPARING THE REST OF THE INCREDIBLE ECOSYSTEM THAT
> IS THE HUMAN BODY. PRECISION-TARGETING AGENTS WILL BE THE NEW STANDARDS OF
> CARE BECAUSE THEY BENEFIT PATIENTS AND HEALTHCARE PROVIDERS BY MINIMIZING
> TRAUMA WHILE CURING THE DISEASE, WHICH, IN TURN, CREATES VALUE FOR SOCIETY AND
> PAYERS ALIKE.
> 
>  
> 
> Bob Duggan
> Chief Executive Officer & Chairman

 




> AS A COMPANY, WE ARE COMMITTED TO KEEPING THE PATIENT AT THE FOREFRONT OF
> EVERYTHING WE DO. WE ARE BELIEVERS IN THE POWER OF INNOVATION AND HOW IT CAN
> CHANGE PATIENTS’ LIVES. MANY OF OUR WORLD-CLASS EXECUTIVES RETURN TO US FROM
> PAST ADVENTURES TO COLLABORATE WITH NEW, TALENTED LEADERS WORKING WITH US FOR
> THE FIRST TIME. OUR COMBINED PAST ACCOMPLISHMENTS AND OUR CURRENT DRIVE SPEAK
> VOLUMES AS TO THE IMPACT WE CAN HAVE ON PATIENTS. OUR MISSION-DRIVEN CULTURE
> TO ALWAYS CONSIDER HOW WE CAN HELP PATIENTS IN EVERY DECISION WE MAKE WILL
> ULTIMATELY GUIDE US TO MAKING A MEANINGFUL DIFFERENCE IN RESOLVING HIGH UNMET
> NEEDS. BOB AND I ARE HUMBLED BY THE OPPORTUNITY TO LEAD THIS IMPRESSIVE GROUP
> OF ACCOMPLISHED EXECUTIVES AND TEAMMATES AS WE SEEK TO EXPAND OUR PIPELINE TO
> ACHIEVE THIS GOAL.
> 
>  
> 
> Maky Zanganeh
> Co-Chief Executive Officer & President

 





PARTNERS


BARDA

Summit is proud to partner with the Biomedical Advanced Research and Development
Authority (BARDA), part of the Office of the Assistant Secretary for
Preparedness and Response (ASPR) at the U.S. Department of Health and Human
Services (HHS), as initially announced on September 11, 2017, on its Phase III
Ri-CoDIFy trial program investigating ridinilazole for the treatment and
reduction of recurrence of C. difficile infection.

BARDA


CARB-X

Summit is proud to partner with CARB-X, as announced on May 18, 2021, to
progress the development of its precision antibiotic candidate, SMT-738, through
its IND-enabling and Phase Ia clinical trials for the treatment of
highly-resistant CRE bacterial infections.

CARB-X


WEBSITE COOKIES

This website uses cookies: Please see our Privacy Policy to understand how we
use cookies. Okay, thanks
 * ABOUT SUMMIT THERAPEUTICS
 * Our Values
 * Our Programmes
 * Discuva Platform
 * Publications

 * Investor Centre
 * Press Releases
 * Reports & Filings
 * Share Price Data
 * Contact

 * Social Media Platforms
 * Twitter
 * Linkedin

© 2022 Summit Therapeutics Inc.

Trademarks, registered or otherwise, are the property of their respective
owner(s). Website Designed and Developed by Carr Kamasa Design

 * Disclaimer
 * Privacy Policy
 * Online Terms of Use
 * Site Map